Eli Lilly and (LLY) Stock

$882.97 12.60 (1.45%)

Market Cap: $838.22B | NYSE

Eli Lilly and Chart

Company Profile

Price: $882.97

Market Cap: $838.22B

Exchange: NYSE

CEO: Mr. David A. Ricks

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 43.00K

Headquarters: Indianapolis, IN

Website: Eli Lilly and

Business Summary

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and News

Buy, Sell, Or Hold LLY Stock At $870?

Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at $13.5 billion, slightly below the consensus estimate of $13.6 billion.

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS , Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Francisco.1 Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.2,3 "Many people living with Crohn's disease have tried available therapies without success or have experienced a loss of efficacy with their treatment," said Edward Barnes, M.D.

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America's health focus across obesity and beyond. LLY's pipeline spans promising Alzheimer's drug donanemab, precision oncology, and AI-led antimicrobials, with OpenAI-backed supercomputing hinting at unknowable high-value future breakthroughs. The company's Q4 showcased 45% revenue growth, robust margins, and manufacturing expansion, with Orforglipron nearing key readouts; yet competition, Medicare pricing, and valuation temper long-term horizons.

Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant

David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight

Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as Mounjaro for Type 2 Diabetes and Zepbound for Obesity, has significantly outperformed competitors, contributing to over 37% of Lilly's revenues. Lilly's diverse portfolio, including cardiometabolic, oncology, and immunology divisions, also showed strong growth, with significant investments in manufacturing to address supply concerns.

Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript

Eli Lilly and Company (NYSE:LLY ) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dr. Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Dave Hyman - Chief Medical Officer Anne White - President of Lilly Neuroscience Jake Van Naarden - President of Lilly Oncology Ilya Yuffa - President of Lilly International Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Tim Anderson - Bank of America Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Chris Schott - JPMorgan Geoff Meacham - Citibank Colleen Garvey - Guggenheim Securities Conor MacKay - BMO Capital Markets Umer Raffat - Evercore Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Dave Risinger - Leerink Partners Akash Tewari - Jefferies Alexandria Hammond - Wolfe Research Chris Shibutani - Goldman Sachs James Shin - Deutsche Bank Trung Huynh - UBS Nicole Germino - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2024 Earnings Call. At this time all participants are in a listen-only mode.

Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates

Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.

Weekly Jobless Claims Exceed Expectations

Weekly Jobless Claims Exceed Expectations.

Why Eli Lilly Stock Popped on Thursday

Eli Lilly (LLY 4.07%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report.

LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split

Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the company's outlook.

Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates

Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its weight loss drugs Mounjaro and Zepbound fell short. Revenue surged 45% year-over-year to $13.53 billion, slightly below the $15.37 billion expected by Wall Street analysts.

Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates

Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago.

Novo, Lilly still leaders in obesity drug development: Barclays

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity drug market.

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.

Lilly says Mounjaro and Zepbound contributed to big revenue boost

Lilly's CEO says that the company has “tremendous momentum” entering 2025.

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short

Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.

Eli Lilly Stock Rises After Earnings Beat

Fourth-quarter adjusted earnings of $5.32 a share beat analysts' estimates of $5.01.

Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.

Lilly reports full Q4 2024 financial results and provides 2025 guidance

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.

Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Eli Lilly and Company LLY will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025.

Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?

Eli Lilly And Co LLY will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $4.94 in EPS and $13.66 billion in revenues as the company reports before market hours.

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.

What Analysts Think of Eli Lilly Stock Ahead of Earnings

Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.

What Thursday's Earnings Mean for This Pharma Giant

Tomorrow, Eli Lilly (LLY), the world's largest drug company, reports earnings before the market opens. The options market is already predicting some major moves.

Healthy Returns: Why people quit weight loss, diabetes drugs within one year

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.

Eli Lilly and Earnings

This section highlights Eli Lilly and's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 29, 2025

Time: Before Market

Est. EPS: $4.72

Status: Unconfirmed

Last Earnings Results

Date: February 06, 2025

EPS: $5.32

Est. EPS: $5.45

Revenue: $13.53B

Earnings Call Transcripts

Transcript	Quarter	Year	Date	Estimated EPS	Actual EPS
Read Transcript	Q4	2024	2025-02-06	$5.45	$5.32
Read Transcript	Q3	2024	2024-10-30	$1.47	$1.18
Read Transcript	Q2	2024	2024-08-08	$2.60	$3.92
Read Transcript	Q1	2024	2024-04-30	$2.46	$2.58
Read Transcript	Q4	2023	2024-02-06	$2.22	$2.49
Read Transcript	Q3	2023	2023-11-02	$-0.08	$0.10
Read Transcript	Q2	2023	2023-08-08	$1.98	$2.11
Read Transcript	Q1	2023	2023-04-27	$1.73	$1.62

Financial Statements

Access annual & quarterly financial statements for Eli Lilly and, including income statements, balance sheets, and cash flow statements..

Breakdown	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Revenue	$34.12B	$28.54B	$28.32B	$24.54B	$22.32B
Cost of Revenue	$7.08B	$6.63B	$7.31B	$5.48B	$4.72B
Gross Profit	$27.04B	$21.91B	$21.01B	$19.06B	$17.60B
Gross Profit Ratio	79.25%	76.77%	74.18%	77.66%	78.85%
Research and Development Expenses	$9.31B	$7.19B	$7.03B	$6.09B	$5.59B
General and Administrative Expenses	$6.94B	$6.44B	$6.43B	$6.12B	$6.21B
Selling and Marketing Expenses	$-	$1.00B	$1.20B	$1.10B	$6.21B
Selling General and Administrative Expenses	$6.94B	$6.44B	$6.43B	$6.12B	$6.21B
Other Expenses	$-	$-52.10M	$112.80M	$1.50B	$611.80M
Operating Expenses	$16.72B	$13.63B	$13.46B	$12.21B	$11.81B
Cost and Expenses	$23.80B	$20.26B	$20.77B	$17.69B	$16.53B
Interest Income	$173.60M	$62.80M	$25.40M	$33.00M	$80.40M
Interest Expense	$485.90M	$331.60M	$339.80M	$359.60M	$400.60M
Depreciation and Amortization	$1.53B	$1.52B	$1.55B	$1.32B	$1.23B
EBITDA	$8.57B	$8.66B	$8.04B	$8.91B	$6.90B
EBITDA Ratio	25.11%	33.05%	30.86%	31.14%	29.59%
Operating Income	$10.33B	$7.13B	$6.36B	$6.06B	$4.97B
Operating Income Ratio	30.26%	24.97%	22.45%	24.69%	22.29%
Total Other Income Expenses Net	$-3.77B	$-1.85B	$-201.60M	$19.10M	$291.60M
Income Before Tax	$6.55B	$6.81B	$6.16B	$7.23B	$5.27B
Income Before Tax Ratio	19.21%	23.85%	21.74%	29.46%	23.59%
Income Tax Expense	$1.31B	$561.60M	$573.80M	$1.04B	$628.00M
Net Income	$5.24B	$6.24B	$5.58B	$6.19B	$4.64B
Net Income Ratio	15.36%	21.88%	19.71%	25.24%	20.78%
EPS	$5.83	$6.93	$6.15	$6.82	$4.98
EPS Diluted	$5.80	$6.90	$6.12	$6.79	$4.96
Weighted Average Shares Outstanding	899.38M	901.74M	906.96M	907.63M	931.06M
Weighted Average Shares Outstanding Diluted	903.28M	904.62M	911.68M	912.50M	935.68M
SEC Filing	Source	Source	Source	Source	Source

Income Statement Charts

Breakdown	September 30, 2024	June 30, 2024	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	June 30, 2022	March 31, 2022	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019
Revenue	$11.44B	$11.30B	$8.77B	$9.35B	$9.50B	$8.31B	$6.96B	$7.30B	$6.94B	$6.49B	$7.81B	$8.00B	$6.77B	$6.74B	$6.81B	$7.44B	$5.74B	$5.50B	$5.86B	$6.11B
Cost of Revenue	$2.17B	$2.17B	$1.53B	$1.66B	$1.86B	$1.81B	$1.63B	$1.55B	$1.58B	$1.43B	$2.07B	$2.05B	$1.43B	$1.95B	$1.88B	$1.72B	$1.33B	$1.22B	$1.22B	$1.28B
Gross Profit	$9.27B	$9.13B	$7.23B	$7.69B	$7.64B	$6.50B	$5.33B	$5.75B	$5.36B	$5.06B	$5.74B	$5.95B	$5.34B	$4.79B	$4.93B	$5.72B	$4.41B	$4.28B	$4.64B	$4.83B
Gross Profit Ratio	81.02%	80.80%	82.50%	82.26%	80.42%	78.26%	76.63%	78.80%	77.25%	77.95%	73.47%	74.37%	78.87%	71.02%	72.40%	76.88%	76.89%	77.78%	79.26%	79.02%
Research and Development Expenses	$2.73B	$2.71B	$2.52B	$2.56B	$2.41B	$2.36B	$1.99B	$2.00B	$1.80B	$1.78B	$1.61B	$1.96B	$1.71B	$1.67B	$1.68B	$1.84B	$1.47B	$1.39B	$1.39B	$1.58B
General and Administrative Expenses	$2.10B	$2.00B	$1.84B	$1.46B	$1.80B	$1.93B	$1.75B	$1.64B	$1.52B	$1.53B	$1.56B	$1.59B	$1.58B	$1.61B	$1.58B	$1.55B	$1.57B	$1.45B	$1.55B	$1.70B
Selling and Marketing Expenses	$-	$114.40M	$116.10M	$461.90M	$-	$-	$-	$1.00B	$92.40M	$94.30M	$-	$1.20B	$-	$71.10M	$-	$1.10B	$-	$1.45B	$1.55B	$1.70B
Selling General and Administrative Expenses	$2.10B	$2.12B	$1.95B	$1.92B	$1.80B	$1.93B	$1.75B	$1.64B	$1.61B	$1.63B	$1.56B	$1.59B	$1.58B	$1.69B	$1.58B	$1.55B	$1.57B	$1.45B	$1.55B	$1.70B
Other Expenses	$-	$-7.80M	$-139.10M	$-129.00M	$52.50M	$37.50M	$104.30M	$318.50M	$73.70M	$70.70M	$-272.80M	$-3.30M	$-559.30M	$56.60M	$403.40M	$560.40M	$242.70M	$528.10M	$167.30M	$345.60M
Operating Expenses	$4.83B	$4.83B	$4.61B	$4.62B	$4.21B	$4.28B	$3.73B	$3.64B	$3.42B	$3.41B	$3.17B	$3.55B	$3.29B	$3.36B	$3.26B	$3.39B	$3.03B	$2.84B	$2.94B	$3.28B
Cost and Expenses	$7.00B	$7.00B	$6.15B	$6.28B	$6.07B	$6.09B	$5.36B	$5.19B	$5.00B	$4.84B	$5.24B	$5.60B	$4.72B	$5.31B	$5.14B	$5.11B	$4.36B	$4.06B	$4.16B	$4.56B
Interest Income	$47.80M	$37.30M	$45.80M	$44.50M	$48.90M	$46.00M	$34.20M	$25.50M	$20.10M	$10.20M	$7.00M	$7.40M	$7.00M	$5.40M	$5.50M	$5.80M	$5.80M	$7.10M	$14.30M	$13.20M
Interest Expense	$192.70M	$183.60M	$133.80M	$93.70M	$124.60M	$120.30M	$102.80M	$84.00M	$81.50M	$81.20M	$84.90M	$81.40M	$83.60M	$86.90M	$87.80M	$89.20M	$89.60M	$88.30M	$92.50M	$95.90M
Depreciation and Amortization	$466.80M	$414.40M	$400.60M	$387.70M	$411.00M	$366.30M	$362.30M	$375.00M	$362.90M	$348.90M	$435.70M	$445.70M	$382.30M	$369.30M	$350.30M	$367.50M	$358.40M	$324.40M	$273.60M	$340.70M
EBITDA	$2.25B	$4.12B	$3.12B	$3.03B	$962.80M	$2.58B	$1.99B	$2.56B	$2.01B	$1.52B	$2.57B	$2.37B	$1.71B	$2.05B	$1.91B	$2.93B	$1.89B	$2.06B	$2.05B	$2.10B
EBITDA Ratio	19.65%	41.75%	36.62%	38.53%	67.38%	27.91%	24.48%	32.77%	34.60%	32.06%	35.03%	35.99%	32.91%	27.59%	31.99%	35.81%	25.80%	30.56%	30.98%	27.86%
Operating Income	$4.43B	$4.30B	$2.62B	$3.08B	$450.40M	$2.13B	$1.49B	$1.84B	$2.04B	$1.73B	$2.40B	$1.92B	$1.88B	$1.43B	$1.16B	$1.99B	$1.28B	$1.20B	$1.59B	$1.40B
Operating Income Ratio	38.77%	38.08%	29.88%	32.91%	4.74%	25.57%	21.47%	25.15%	29.38%	26.69%	30.78%	23.97%	27.78%	21.19%	16.98%	26.78%	22.27%	21.76%	27.15%	22.90%
Total Other Income Expenses Net	$-2.85B	$-786.90M	$-199.50M	$-569.30M	$-3.00B	$-133.90M	$-69.30M	$-111.10M	$-379.90M	$-653.90M	$-609.60M	$-77.30M	$-886.10M	$165.50M	$-189.80M	$83.50M	$-56.50M	$169.20M	$-67.70M	$59.20M
Income Before Tax	$1.59B	$3.52B	$2.54B	$2.51B	$427.20M	$2.09B	$1.53B	$2.10B	$1.57B	$1.09B	$2.05B	$1.84B	$1.25B	$1.59B	$1.48B	$2.47B	$1.44B	$1.64B	$1.68B	$1.66B
Income Before Tax Ratio	13.89%	31.12%	28.92%	26.82%	4.50%	25.13%	21.98%	28.71%	22.55%	16.81%	26.29%	23.00%	18.39%	23.65%	21.69%	33.19%	25.04%	29.89%	28.67%	27.20%
Income Tax Expense	$618.10M	$550.20M	$293.20M	$319.20M	$484.60M	$325.70M	$184.80M	$158.70M	$113.80M	$138.40M	$150.70M	$113.80M	$135.20M	$203.70M	$121.10M	$352.30M	$228.80M	$231.70M	$223.40M	$167.40M
Net Income	$970.30M	$2.97B	$2.24B	$2.19B	$-57.40M	$1.76B	$1.34B	$1.94B	$1.45B	$952.50M	$1.90B	$1.73B	$1.11B	$1.39B	$1.36B	$2.12B	$1.21B	$1.41B	$1.46B	$1.50B
Net Income Ratio	8.48%	26.25%	25.58%	23.41%	-0.60%	21.21%	19.32%	26.54%	20.91%	14.68%	24.36%	21.58%	16.39%	20.63%	19.91%	28.45%	21.05%	25.68%	24.86%	24.46%
EPS	$1.08	$3.29	$2.49	$2.31	$-0.06	$1.96	$1.49	$2.04	$1.61	$1.06	$2.11	$1.81	$1.22	$1.53	$1.49	$2.21	$1.33	$1.56	$1.60	$1.56
EPS Diluted	$1.07	$3.28	$2.48	$2.31	$-0.06	$1.95	$1.49	$2.04	$1.61	$1.05	$2.10	$1.81	$1.22	$1.53	$1.49	$2.21	$1.33	$1.55	$1.60	$1.56
Weighted Average Shares Outstanding	901.00M	900.90M	900.80M	949.38M	899.80M	899.70M	901.00M	950.18M	900.70M	900.30M	903.70M	925.75M	906.70M	907.30M	908.80M	912.59M	907.20M	907.20M	908.20M	914.68M
Weighted Average Shares Outstanding Diluted	905.00M	904.20M	903.80M	949.38M	899.80M	902.70M	903.30M	950.18M	903.80M	902.90M	906.40M	953.65M	910.80M	910.40M	912.40M	956.59M	911.40M	910.90M	911.70M	957.53M
SEC Filing	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source

Annual Balance Sheet

Annual
Quarterly

Breakdown	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Cash and Cash Equivalents	$2.82B	$2.07B	$3.82B	$3.66B	$2.34B
Short Term Investments	$109.10M	$144.80M	$90.10M	$24.20M	$101.00M
Cash and Short Term Investments	$2.93B	$2.21B	$3.91B	$3.68B	$2.44B
Net Receivables	$11.34B	$8.56B	$8.13B	$6.93B	$5.54B
Inventory	$5.77B	$4.31B	$3.89B	$3.98B	$3.19B
Other Current Assets	$5.69B	$2.95B	$2.53B	$2.87B	$2.54B
Total Current Assets	$25.73B	$18.03B	$18.45B	$17.46B	$13.71B
Property Plant Equipment Net	$12.91B	$10.14B	$8.99B	$8.68B	$8.40B
Goodwill	$4.94B	$4.07B	$3.89B	$3.77B	$3.68B
Intangible Assets	$6.91B	$7.21B	$7.69B	$7.45B	$6.62B
Goodwill and Intangible Assets	$11.85B	$11.28B	$11.58B	$11.22B	$10.30B
Long Term Investments	$3.05B	$2.90B	$3.21B	$2.97B	$1.96B
Tax Assets	$5.48B	$2.79B	$2.49B	$2.83B	$2.57B
Other Non-Current Assets	$4.99B	$4.34B	$4.08B	$3.48B	$2.34B
Total Non-Current Assets	$38.28B	$31.46B	$30.35B	$29.17B	$25.58B
Other Assets	$-	$-	$-	$-	$-
Total Assets	$64.01B	$49.49B	$48.81B	$46.63B	$39.29B
Account Payables	$2.60B	$1.93B	$1.67B	$1.61B	$1.41B
Short Term Debt	$6.90B	$1.50B	$1.54B	$8.70M	$1.62B
Tax Payables	$3.85B	$475.10M	$126.90M	$495.10M	$160.60M
Deferred Revenue	$-	$-	$8.82B	$8.12B	$6.68B
Other Current Liabilities	$13.94B	$13.23B	$11.72B	$10.37B	$8.59B
Total Current Liabilities	$27.29B	$17.14B	$15.05B	$12.48B	$11.78B
Long Term Debt	$18.32B	$14.74B	$15.35B	$16.59B	$14.30B
Deferred Revenue Non-Current	$-	$-	$5.87B	$7.93B	$7.31B
Deferred Tax Liabilities Non-Current	$-	$87.30M	$1.73B	$2.10B	$2.19B
Other Non-Current Liabilities	$7.53B	$6.75B	$7.52B	$9.64B	$8.32B
Total Non-Current Liabilities	$25.85B	$21.58B	$24.60B	$28.33B	$24.81B
Other Liabilities	$-	$-	$-	$-	$-
Total Liabilities	$53.14B	$38.71B	$39.65B	$40.81B	$36.59B
Preferred Stock	$-	$-	$-	$-	$-
Common Stock	$593.60M	$594.10M	$596.30M	$598.20M	$598.80M
Retained Earnings	$10.31B	$10.04B	$8.96B	$7.83B	$4.92B
Accumulated Other Comprehensive Income Loss	$-4.33B	$-3.84B	$-4.34B	$-6.50B	$-6.52B
Other Total Stockholders Equity	$4.19B	$6.87B	$6.78B	$6.72B	$6.62B
Total Stockholders Equity	$10.77B	$10.65B	$8.98B	$5.64B	$2.61B
Total Equity	$10.86B	$10.78B	$9.15B	$5.83B	$2.70B
Total Liabilities and Stockholders Equity	$64.01B	$49.49B	$48.81B	$46.63B	$39.29B
Minority Interest	$91.80M	$125.60M	$175.60M	$183.60M	$92.20M
Total Liabilities and Total Equity	$64.01B	$49.49B	$48.81B	$46.63B	$39.29B
Total Investments	$3.16B	$3.05B	$3.30B	$2.99B	$2.06B
Total Debt	$25.23B	$16.24B	$16.88B	$16.60B	$15.80B
Net Debt	$22.41B	$14.17B	$13.07B	$12.94B	$13.47B

Balance Sheet Charts

Breakdown	September 30, 2024	June 30, 2024	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	June 30, 2022	March 31, 2022	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019
Cash and Cash Equivalents	$3.37B	$3.22B	$2.46B	$2.82B	$2.38B	$2.69B	$3.55B	$2.07B	$2.62B	$2.62B	$2.46B	$3.82B	$3.79B	$3.22B	$3.00B	$3.66B	$3.60B	$2.37B	$1.70B	$2.34B
Short Term Investments	$149.40M	$140.40M	$126.10M	$109.10M	$113.10M	$134.60M	$123.40M	$144.80M	$124.70M	$113.80M	$109.10M	$90.10M	$37.10M	$51.20M	$49.00M	$24.20M	$35.00M	$22.80M	$78.40M	$101.00M
Cash and Short Term Investments	$3.52B	$3.36B	$2.59B	$2.93B	$2.49B	$2.83B	$3.67B	$2.21B	$2.74B	$2.74B	$2.57B	$3.91B	$3.83B	$3.27B	$3.05B	$3.68B	$3.63B	$2.39B	$1.78B	$2.44B
Net Receivables	$12.05B	$13.08B	$10.01B	$11.34B	$10.36B	$9.17B	$9.02B	$8.56B	$8.32B	$7.67B	$7.81B	$8.13B	$7.03B	$6.90B	$6.66B	$6.93B	$5.84B	$5.78B	$6.35B	$5.54B
Inventory	$7.46B	$6.48B	$6.10B	$5.77B	$4.90B	$4.80B	$4.54B	$4.31B	$3.83B	$3.90B	$3.89B	$3.89B	$3.91B	$3.82B	$3.66B	$3.98B	$3.56B	$3.31B	$3.10B	$3.19B
Other Current Assets	$8.39B	$7.28B	$6.49B	$5.69B	$5.25B	$4.53B	$3.58B	$2.95B	$5.48B	$5.61B	$5.40B	$5.06B	$6.10B	$6.59B	$6.47B	$5.74B	$6.42B	$6.21B	$5.52B	$5.08B
Total Current Assets	$31.42B	$30.20B	$25.19B	$25.73B	$23.01B	$21.33B	$20.81B	$18.03B	$17.64B	$17.12B	$16.96B	$18.45B	$17.81B	$17.30B	$16.60B	$17.46B	$16.24B	$14.58B	$13.99B	$13.71B
Property Plant Equipment Net	$16.17B	$14.83B	$13.62B	$12.91B	$11.86B	$11.28B	$10.55B	$10.14B	$9.31B	$9.13B	$9.10B	$8.99B	$8.92B	$8.86B	$8.63B	$8.68B	$8.28B	$7.98B	$7.90B	$8.40B
Goodwill	$5.77B	$5.77B	$4.94B	$4.94B	$4.09B	$4.08B	$4.07B	$4.07B	$3.89B	$3.89B	$3.89B	$3.89B	$3.88B	$3.88B	$3.88B	$3.77B	$3.73B	$3.72B	$3.78B	$3.68B
Intangible Assets	$6.54B	$6.64B	$6.76B	$6.91B	$6.78B	$6.90B	$7.09B	$7.21B	$7.12B	$7.50B	$7.48B	$7.69B	$7.89B	$7.99B	$8.09B	$7.45B	$7.59B	$7.71B	$7.77B	$6.62B
Goodwill and Intangible Assets	$12.31B	$12.40B	$11.70B	$11.85B	$10.87B	$10.98B	$11.16B	$11.28B	$11.02B	$11.39B	$11.37B	$11.58B	$11.77B	$11.87B	$11.97B	$11.22B	$11.31B	$11.44B	$11.55B	$10.30B
Long Term Investments	$3.20B	$2.92B	$3.09B	$3.05B	$2.69B	$2.75B	$2.75B	$2.90B	$2.57B	$2.59B	$2.73B	$3.21B	$3.35B	$3.47B	$3.23B	$2.97B	$2.48B	$2.41B	$2.15B	$1.96B
Tax Assets	$7.39B	$6.66B	$5.63B	$5.48B	$4.57B	$3.81B	$3.41B	$2.79B	$2.38B	$2.37B	$2.46B	$2.49B	$2.63B	$2.67B	$2.65B	$2.83B	$2.56B	$2.48B	$2.47B	$2.57B
Other Non-Current Assets	$5.12B	$4.86B	$4.71B	$4.99B	$4.91B	$4.67B	$4.49B	$4.34B	$4.54B	$4.47B	$4.29B	$4.08B	$3.71B	$3.64B	$3.76B	$3.48B	$3.08B	$3.08B	$3.04B	$2.34B
Total Non-Current Assets	$44.19B	$41.67B	$38.75B	$38.28B	$34.91B	$33.48B	$32.35B	$31.46B	$29.82B	$29.95B	$29.95B	$30.35B	$30.38B	$30.51B	$30.23B	$29.17B	$27.71B	$27.39B	$27.11B	$25.58B
Other Assets	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$--0.00B	$-	$-	$-	$-	$-
Total Assets	$75.61B	$71.87B	$63.94B	$64.01B	$57.92B	$54.81B	$53.16B	$49.49B	$47.46B	$47.06B	$46.92B	$48.81B	$48.19B	$47.81B	$46.84B	$46.63B	$43.95B	$41.97B	$41.10B	$39.29B
Account Payables	$2.89B	$2.92B	$2.47B	$2.60B	$2.44B	$2.47B	$2.02B	$1.93B	$1.68B	$1.66B	$1.43B	$1.67B	$1.57B	$1.60B	$1.64B	$1.61B	$1.43B	$1.25B	$1.21B	$1.41B
Short Term Debt	$2.07B	$5.16B	$1.65B	$6.90B	$2.24B	$661.60M	$3.10M	$1.50B	$1.74B	$2.12B	$1.36B	$1.54B	$1.56B	$1.78B	$4.90M	$8.70M	$587.50M	$1.26B	$3.25B	$1.50B
Tax Payables	$3.88B	$3.50B	$4.19B	$3.85B	$1.98B	$1.23B	$1.53B	$475.10M	$685.60M	$126.60M	$598.30M	$126.90M	$203.50M	$529.90M	$791.60M	$495.10M	$1.17B	$1.46B	$667.40M	$160.60M
Deferred Revenue	$-	$3.50B	$4.19B	$14.51B	$1.98B	$1.23B	$-	$-	$-	$-	$-	$8.82B	$8.23B	$9.09B	$7.26B	$8.12B	$7.71B	$7.42B	$5.94B	$6.68B
Other Current Liabilities	$15.83B	$15.54B	$10.28B	$13.94B	$15.34B	$14.55B	$12.46B	$13.23B	$11.54B	$11.71B	$10.00B	$11.72B	$10.35B	$11.19B	$9.28B	$10.37B	$8.79B	$8.02B	$7.49B	$8.71B
Total Current Liabilities	$24.67B	$27.12B	$18.60B	$27.29B	$22.00B	$18.91B	$16.01B	$17.14B	$15.65B	$15.62B	$13.39B	$15.05B	$13.68B	$15.09B	$11.71B	$12.48B	$11.98B	$11.99B	$12.61B	$11.78B
Long Term Debt	$29.05B	$23.73B	$24.56B	$18.32B	$17.92B	$18.16B	$18.88B	$14.74B	$14.14B	$14.69B	$15.15B	$15.35B	$15.52B	$14.74B	$16.20B	$16.59B	$16.33B	$15.06B	$13.98B	$14.30B
Deferred Revenue Non-Current	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$5.87B	$7.65B	$7.66B	$7.89B	$7.93B	$6.83B	$6.78B	$7.25B	$7.31B
Deferred Tax Liabilities Non-Current	$-	$-	$-	$-	$-	$-	$-	$87.30M	$171.90M	$862.50M	$1.29B	$1.73B	$1.63B	$1.86B	$2.20B	$2.10B	$2.11B	$2.04B	$2.19B	$2.19B
Other Non-Current Liabilities	$7.57B	$7.39B	$7.89B	$7.53B	$6.69B	$6.59B	$6.98B	$6.75B	$7.33B	$7.23B	$7.63B	$7.52B	$9.40B	$9.46B	$9.62B	$9.64B	$8.53B	$8.60B	$9.13B	$8.32B
Total Non-Current Liabilities	$36.61B	$31.12B	$32.45B	$25.85B	$24.61B	$24.75B	$25.86B	$21.58B	$21.64B	$22.78B	$24.07B	$24.60B	$26.55B	$26.05B	$28.02B	$28.33B	$26.97B	$25.71B	$25.30B	$24.81B
Other Liabilities	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Total Liabilities	$61.29B	$58.24B	$51.05B	$53.14B	$46.61B	$43.66B	$41.87B	$38.71B	$37.30B	$38.40B	$37.46B	$39.65B	$40.23B	$41.15B	$39.74B	$40.81B	$38.95B	$37.70B	$37.91B	$36.59B
Preferred Stock	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Common Stock	$593.90M	$594.20M	$594.20M	$593.60M	$593.60M	$593.60M	$593.50M	$594.10M	$594.10M	$594.10M	$594.10M	$596.30M	$598.20M	$598.10M	$599.70M	$598.20M	$598.10M	$598.10M	$598.10M	$598.80M
Retained Earnings	$13.63B	$13.18B	$12.55B	$10.31B	$10.31B	$10.37B	$10.64B	$10.04B	$10.01B	$8.56B	$9.37B	$8.96B	$9.64B	$8.53B	$9.18B	$7.83B	$7.15B	$6.62B	$5.88B	$4.92B
Accumulated Other Comprehensive Income Loss	$-4.27B	$-4.38B	$-4.30B	$-4.33B	$-3.78B	$-3.79B	$-3.78B	$-3.84B	$-4.30B	$-4.29B	$-4.23B	$-4.34B	$-6.17B	$-6.29B	$-6.40B	$-6.50B	$-6.56B	$-6.68B	$-6.89B	$-6.52B
Other Total Stockholders Equity	$4.29B	$4.17B	$3.96B	$4.19B	$4.10B	$3.89B	$3.73B	$3.86B	$3.77B	$3.68B	$3.59B	$3.77B	$3.69B	$3.60B	$3.51B	$3.71B	$3.63B	$3.56B	$3.49B	$3.61B
Total Stockholders Equity	$14.24B	$13.56B	$12.81B	$10.77B	$11.22B	$11.06B	$11.19B	$10.65B	$10.07B	$8.54B	$9.33B	$8.98B	$7.76B	$6.44B	$6.90B	$5.64B	$4.83B	$4.09B	$3.08B	$2.61B
Total Equity	$14.32B	$13.64B	$12.90B	$10.86B	$11.31B	$11.15B	$11.29B	$10.78B	$10.17B	$8.66B	$9.46B	$9.15B	$7.95B	$6.66B	$7.10B	$5.83B	$5.00B	$4.27B	$3.20B	$2.70B
Total Liabilities and Stockholders Equity	$75.61B	$71.87B	$63.94B	$64.01B	$57.92B	$54.81B	$53.16B	$49.49B	$47.46B	$47.06B	$46.92B	$48.81B	$48.19B	$47.81B	$46.84B	$46.63B	$43.95B	$41.97B	$41.10B	$39.29B
Minority Interest	$80.70M	$73.50M	$85.20M	$91.80M	$87.00M	$85.50M	$104.50M	$125.60M	$95.80M	$114.50M	$131.20M	$175.60M	$197.10M	$219.10M	$200.60M	$183.60M	$169.10M	$179.10M	$118.40M	$92.20M
Total Liabilities and Total Equity	$75.61B	$71.87B	$63.94B	$64.01B	$57.92B	$54.81B	$53.16B	$49.49B	$47.46B	$47.06B	$46.92B	$48.81B	$48.19B	$47.81B	$46.84B	$46.63B	$43.95B	$41.97B	$41.10B	$39.29B
Total Investments	$3.35B	$3.06B	$3.21B	$3.16B	$2.80B	$2.88B	$2.87B	$3.05B	$2.70B	$2.70B	$2.84B	$3.30B	$3.39B	$3.53B	$3.28B	$2.99B	$2.51B	$2.43B	$2.23B	$2.06B
Total Debt	$31.12B	$28.89B	$26.21B	$25.23B	$20.17B	$18.82B	$18.88B	$16.24B	$15.89B	$16.81B	$16.51B	$16.88B	$17.09B	$16.52B	$16.20B	$16.60B	$16.92B	$16.33B	$17.23B	$15.80B
Net Debt	$27.75B	$25.67B	$23.75B	$22.41B	$17.79B	$16.13B	$15.34B	$14.17B	$13.27B	$14.19B	$14.05B	$13.07B	$13.30B	$13.30B	$13.20B	$12.94B	$13.33B	$13.96B	$15.53B	$13.47B

Annual Cash Flow

Annual
Quarterly

Breakdown	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Net Income	$5.24B	$6.24B	$5.58B	$6.19B	$8.32B
Depreciation and Amortization	$1.53B	$1.52B	$1.55B	$1.32B	$1.23B
Deferred Income Tax	$-2.34B	$-2.19B	$-802.30M	$-134.50M	$62.40M
Stock Based Compensation	$628.50M	$371.10M	$342.80M	$308.10M	$312.40M
Change in Working Capital	$-3.06B	$-14.50M	$-1.02B	$-747.40M	$-1.69B
Accounts Receivables	$-2.45B	$-299.60M	$-1.28B	$-1.35B	$-127.20M
Inventory	$-1.43B	$-599.70M	$-235.90M	$-533.40M	$-258.70M
Accounts Payables	$4.27B	$1.33B	$-664.10M	$1.27B	$-477.70M
Other Working Capital	$-3.45B	$-446.90M	$1.16B	$-135.10M	$-823.60M
Other Non Cash Items	$2.24B	$1.15B	$1.61B	$-444.20M	$-3.40B
Net Cash Provided by Operating Activities	$4.24B	$7.08B	$7.26B	$6.50B	$4.84B
Investments in Property Plant and Equipment	$-3.45B	$-2.48B	$-1.87B	$-2.03B	$-1.35B
Acquisitions Net	$-1.04B	$-327.20M	$-747.40M	$-849.30M	$-6.94B
Purchases of Investments	$-829.00M	$-707.60M	$-1.01B	$-370.10M	$-290.20M
Sales Maturities of Investments	$700.30M	$463.60M	$847.40M	$886.80M	$746.40M
Other Investing Activities	$-2.53B	$-206.40M	$24.30M	$102.80M	$-248.70M
Net Cash Used for Investing Activities	$-7.15B	$-3.26B	$-2.76B	$-2.26B	$-8.08B
Debt Repayment	$8.65B	$-62.00M	$501.40M	$291.60M	$4.69B
Common Stock Issued	$-	$-	$-	$-	$-
Common Stock Repurchased	$-750.00M	$-1.50B	$-1.25B	$-500.00M	$-4.40B
Dividends Paid	$-4.07B	$-3.54B	$-3.09B	$-2.69B	$-2.41B
Other Financing Activities	$-335.00M	$-308.90M	$-295.90M	$-241.60M	$-200.10M
Net Cash Used Provided by Financing Activities	$3.50B	$-5.41B	$-4.13B	$-3.14B	$-2.32B
Effect of Forex Changes on Cash	$168.60M	$-167.60M	$-205.70M	$216.00M	$-89.90M
Net Change in Cash	$751.60M	$-1.75B	$161.40M	$1.32B	$-5.66B
Cash at End of Period	$2.82B	$2.07B	$3.82B	$3.66B	$2.34B
Cash at Beginning of Period	$2.07B	$3.82B	$3.66B	$2.34B	$8.00B
Operating Cash Flow	$4.24B	$7.08B	$7.26B	$6.50B	$4.84B
Capital Expenditure	$-7.39B	$-2.48B	$-1.87B	$-2.03B	$-1.35B
Free Cash Flow	$-3.15B	$4.60B	$5.39B	$4.47B	$3.48B

Cash Flow Charts

Breakdown	September 30, 2024	June 30, 2024	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	June 30, 2022	March 31, 2022	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019
Net Income	$970.30M	$2.97B	$2.24B	$2.19B	$-57.40M	$1.76B	$1.34B	$1.94B	$1.45B	$952.50M	$1.90B	$1.73B	$1.11B	$1.39B	$1.36B	$2.12B	$1.21B	$1.41B	$1.46B	$1.50B
Depreciation and Amortization	$466.80M	$414.40M	$400.60M	$387.70M	$411.00M	$366.30M	$362.30M	$375.00M	$362.90M	$348.90M	$435.70M	$445.70M	$382.30M	$369.30M	$350.30M	$367.50M	$358.40M	$324.40M	$273.60M	$340.70M
Deferred Income Tax	$-429.80M	$-1.01B	$-279.00M	$-506.20M	$-844.30M	$-431.10M	$-559.40M	$10.40M	$-1.07B	$-618.40M	$-506.60M	$-92.50M	$-296.00M	$-294.70M	$-119.10M	$-200.70M	$159.70M	$-104.70M	$11.20M	$85.80M
Stock Based Compensation	$133.20M	$211.10M	$159.40M	$120.20M	$215.60M	$161.50M	$131.20M	$92.90M	$85.10M	$92.10M	$101.00M	$75.30M	$90.10M	$91.90M	$85.50M	$87.80M	$71.70M	$76.80M	$71.80M	$81.60M
Change in Working Capital	$-9.80M	$-1.40B	$-1.75B	$-3.17B	$793.30M	$-840.20M	$164.10M	$-836.00M	$939.10M	$-72.10M	$-45.50M	$-474.50M	$-666.50M	$221.20M	$-102.80M	$-515.20M	$249.40M	$926.50M	$-1.41B	$76.50M
Accounts Receivables	$-	$-	$-	$-2.45B	$-	$-	$-	$-299.60M	$-	$-	$-	$-1.28B	$-	$-	$-	$-1.35B	$-	$-	$-	$-127.20M
Inventory	$-	$-	$-	$-1.43B	$-	$-	$-	$-599.70M	$-	$-	$-	$-235.90M	$-	$-	$-	$-533.40M	$-	$-	$-	$-258.70M
Accounts Payables	$-	$-	$-	$4.27B	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Other Working Capital	$-9.80M	$-1.40B	$-1.75B	$-3.57B	$793.30M	$-840.20M	$164.10M	$63.30M	$939.10M	$-72.10M	$-34.30M	$-474.50M	$-666.50M	$221.20M	$-102.80M	$-515.20M	$249.40M	$926.50M	$-1.41B	$76.50M
Other Non Cash Items	$2.58B	$1.32B	$409.10M	$669.00M	$1.67B	$-387.80M	$287.50M	$-300.00K	$416.60M	$117.70M	$611.70M	$476.40M	$1.01B	$-2.40M	$128.20M	$-41.00M	$-241.00M	$-139.60M	$-22.60M	$-116.60M
Net Cash Provided by Operating Activities	$3.71B	$1.47B	$1.17B	$-311.90M	$2.19B	$631.90M	$1.73B	$1.58B	$2.18B	$820.70M	$2.50B	$2.16B	$1.63B	$1.78B	$1.70B	$1.82B	$1.81B	$2.50B	$382.40M	$1.96B
Investments in Property Plant and Equipment	$-1.17B	$-1.40B	$-986.30M	$-1.65B	$-4.00B	$-836.30M	$-903.50M	$-555.60M	$-620.20M	$-451.00M	$-857.20M	$-394.20M	$-455.60M	$-531.30M	$-492.10M	$-819.50M	$-415.10M	$-523.20M	$-271.30M	$-326.50M
Acquisitions Net	$-	$-947.70M	$-	$-1.62B	$-1.43B	$-98.10M	$-	$-327.20M	$-	$-	$-	$-102.80M	$-118.80M	$-150.00M	$-747.40M	$-364.80M	$-22.00M	$-241.40M	$-849.30M	$-19.20M
Purchases of Investments	$-294.80M	$-157.40M	$-141.50M	$-275.00M	$-150.80M	$-234.20M	$-169.00M	$-168.50M	$-254.80M	$-153.00M	$-131.30M	$-275.40M	$-208.30M	$-218.80M	$-310.90M	$-135.00M	$-80.30M	$-71.80M	$-83.00M	$-59.40M
Sales Maturities of Investments	$99.80M	$213.60M	$111.90M	$68.90M	$133.40M	$154.60M	$343.40M	$128.90M	$108.60M	$118.00M	$108.10M	$263.60M	$100.60M	$194.40M	$288.80M	$193.90M	$169.70M	$431.90M	$91.30M	$131.70M
Other Investing Activities	$-2.64B	$95.60M	$-65.20M	$557.70M	$2.36B	$554.90M	$40.30M	$61.90M	$-157.00M	$22.10M	$-133.40M	$129.80M	$65.60M	$222.40M	$-21.90M	$451.30M	$34.20M	$194.10M	$51.40M	$232.00M
Net Cash Used for Investing Activities	$-4.00B	$-2.20B	$-1.18B	$-2.92B	$-3.08B	$-459.10M	$-688.80M	$-860.50M	$-923.40M	$-463.90M	$-1.01B	$-379.00M	$-616.50M	$-483.30M	$-1.28B	$-674.10M	$-313.50M	$-210.40M	$-1.06B	$-41.40M
Debt Repayment	$1.88B	$2.74B	$1.25B	$4.59B	$1.59B	$-	$2.46B	$-243.30M	$-375.90M	$767.60M	$-210.40M	$-2.60M	$307.70M	$200.00M	$-3.70M	$-580.10M	$394.80M	$-995.50M	$1.47B	$-221.50M
Common Stock Issued	$-	$-	$-	$2.46B	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Common Stock Repurchased	$-446.10M	$-	$-	$750.00M	$-	$-	$-750.00M	$1.50B	$-	$-	$-1.50B	$-750.00M	$-	$-500.00M	$-	$-	$-	$-	$-500.00M	$-300.00M
Dividends Paid	$-1.17B	$-1.17B	$-1.17B	$-1.02B	$-1.02B	$-1.02B	$-1.02B	$-884.40M	$-882.20M	$-883.70M	$-885.50M	$-773.30M	$-770.40M	$-768.30M	$-774.80M	$-670.00M	$-671.60M	$-674.20M	$-671.30M	$-587.20M
Other Financing Activities	$-47.30M	$-8.00M	$-389.80M	$-31.60M	$-6.80M	$-15.60M	$-281.00M	$-13.70M	$-5.20M	$-7.60M	$-282.40M	$-600.00K	$-500.00K	$-14.90M	$-279.90M	$-41.40M	$-2.30M	$-3.50M	$-194.40M	$-4.90M
Net Cash Used Provided by Financing Activities	$211.30M	$1.56B	$-311.30M	$3.54B	$572.00M	$-1.03B	$412.30M	$-1.14B	$-1.26B	$-123.70M	$-2.88B	$-1.53B	$-463.20M	$-1.08B	$-1.06B	$-1.29B	$-279.10M	$-1.67B	$106.70M	$-1.11B
Effect of Forex Changes on Cash	$226.90M	$-59.60M	$-35.50M	$129.30M	$5.30M	$9.20M	$24.80M	$-128.20M	$-3.60M	$-69.40M	$33.60M	$-220.70M	$16.60M	$8.60M	$-10.20M	$212.20M	$16.20M	$54.30M	$-66.70M	$-35.00M
Net Change in Cash	$145.40M	$763.40M	$-358.40M	$437.80M	$-313.70M	$-851.40M	$1.48B	$-550.40M	$-5.50M	$163.70M	$-1.36B	$30.30M	$568.20M	$217.60M	$-654.70M	$61.80M	$1.23B	$666.10M	$-638.50M	$773.70M
Cash at End of Period	$3.37B	$3.22B	$2.46B	$2.82B	$2.38B	$2.69B	$3.55B	$2.07B	$2.62B	$2.62B	$2.46B	$3.82B	$3.79B	$3.22B	$3.00B	$3.66B	$3.60B	$2.37B	$1.70B	$2.34B
Cash at Beginning of Period	$3.22B	$2.46B	$2.82B	$2.38B	$2.69B	$3.55B	$2.07B	$2.62B	$2.62B	$2.46B	$3.82B	$3.79B	$3.22B	$3.00B	$3.66B	$3.60B	$2.37B	$1.70B	$2.34B	$1.56B
Operating Cash Flow	$3.71B	$1.47B	$1.17B	$-311.90M	$2.19B	$631.90M	$1.73B	$1.58B	$2.18B	$820.70M	$2.50B	$2.16B	$1.63B	$1.78B	$1.70B	$1.82B	$1.81B	$2.50B	$382.40M	$1.96B
Capital Expenditure	$-4.17B	$-1.40B	$-986.30M	$-1.65B	$-4.00B	$-836.30M	$-903.50M	$-555.60M	$-620.20M	$-451.00M	$-857.20M	$-394.20M	$-455.60M	$-531.30M	$-492.10M	$-819.50M	$-415.10M	$-523.20M	$-271.30M	$-326.50M
Free Cash Flow	$-458.90M	$63.40M	$179.70M	$-1.96B	$-1.81B	$-204.40M	$827.10M	$1.02B	$1.56B	$369.70M	$1.64B	$1.76B	$1.18B	$1.24B	$1.21B	$995.70M	$1.39B	$1.97B	$111.10M	$1.64B

Build your own charts

Eli Lilly and Stock Forecast

Analyst ratings, price targets, and earnings estimates for LLY.

LLY Analyst Ratings

Strong Buy

Buy

Hold

Sell

Based on 21 analysts in the past 3 months

LLY Stock 12 Month Forecast

$960.00

▲ (8.72% Upside)

Highest Price Target

$ (0.0%)

Average Price Target

$960.00 (8.7%)

Lowest Price Target

$ (0.0%)

Based on 2 analysts in the last 3 months

Recent Price Targets

Recommendation Trends

Analyst Estimates

Revenue Estimates

High $62.05B

Average $58.81B

Low $57.50B

19 analysts

Net Income Estimates

High $22.60B

Average $21.09B

Low $19.59B

19 analysts

EPS Estimates

High $25.02

Average $22.63

Low $21.69

13 analysts

Revenue Estimates

High $81.64B

Average $70.35B

Low $62.67B

24 analysts

Net Income Estimates

High $33.45B

Average $24.83B

Low $21.18B

24 analysts

EPS Estimates

High $37.03

Average $29.52

Low $23.45

16 analysts

Revenue Estimates

High $80.62B

Average $80.48B

Low $80.35B

14 analysts

Net Income Estimates

High $38.72B

Average $30.41B

Low $24.45B

14 analysts

EPS Estimates

High $42.87

Average $36.34

Low $27.06

6 analysts

Revenue Estimates

High $97.67B

Average $88.77B

Low $82.73B

6 analysts

Net Income Estimates

High $42.17B

Average $37.31B

Low $34.01B

6 analysts

EPS Estimates

High $46.69

Average $41.31

Low $37.65

3 analysts

Revenue Estimates

High $106.32B

Average $96.63B

Low $90.06B

8 analysts

Net Income Estimates

High $47.27B

Average $41.82B

Low $38.12B

8 analysts

EPS Estimates

High $52.33

Average $46.30

Low $42.20

3 analysts

Latest Price Target Updates

Date	Analyst	Firm	Price Target	Price When Posted	Upside
Jan 17, 2025	Andrew Berens	Leerink Partners	$950.00	$740.15	28.4%
Jan 16, 2025	Kerry Holford	Berenberg Bank	$970.00	$746.74	29.9%
Oct 31, 2024	Evan David Seigerman	BMO Capital	$1010.00	$829.74	21.7%
Oct 14, 2024	Andrew Berens	Leerink Partners	$990.00	$932.06	6.2%
Sep 13, 2024	Peter Verdult	Citigroup	$1060.00	$935.02	13.4%
Aug 27, 2024	Terence Flynn	Morgan Stanley	$1106.00	$957.51	15.5%
Aug 14, 2024	Kerry Holford	Berenberg Bank	$1050.00	$908.05	15.6%
Aug 12, 2024	James Shin	Deutsche Bank	$1025.00	$891.68	15.0%
Aug 09, 2024	Chris Shibutani	Goldman Sachs	$856.00	$891.68	-4.0%
Aug 09, 2024	Mohit Bansal	Wells Fargo	$1000.00	$845.31	18.3%

Eli Lilly and Dividends

Explore Eli Lilly and's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

0.78%

Dividend Payout Ratio

77.65%

Dividend Paid & Capex Coverage Ratio

0.37x

Eli Lilly and Dividend History

Dividend	Adjusted Dividend	Date	Record Date	Payment Date	Declaration Date
$1.5	$1.5	February 14, 2025	February 14, 2025	March 10, 2025	December 09, 2024
$1.3	$1.3	November 15, 2024	November 15, 2024	December 10, 2024	October 28, 2024
$1.3	$1.3	August 15, 2024	August 15, 2024	September 10, 2024	June 24, 2024
$1.3	$1.3	May 15, 2024	May 16, 2024	June 10, 2024	May 06, 2024
$1.3	$1.3	February 14, 2024	February 15, 2024	March 08, 2024	December 08, 2023
$1.13	$1.13	November 14, 2023	November 15, 2023	December 08, 2023	November 01, 2023
$1.13	$1.13	August 14, 2023	August 15, 2023	September 08, 2023	June 26, 2023
$1.13	$1.13	May 12, 2023	May 15, 2023	June 09, 2023	May 01, 2023
$1.13	$1.13	February 14, 2023	February 15, 2023	March 10, 2023	December 12, 2022
$0.98	$0.98	November 14, 2022	November 15, 2022	December 09, 2022	October 17, 2022
$0.98	$0.98	August 12, 2022	August 15, 2022	September 09, 2022	June 27, 2022
$0.98	$0.98	May 13, 2022	May 16, 2022	June 10, 2022	May 02, 2022
$0.98	$0.98	February 14, 2022	February 15, 2022	March 10, 2022	December 13, 2021
$0.85	$0.85	November 12, 2021	November 15, 2021	December 10, 2021	October 18, 2021
$0.85	$0.85	August 12, 2021	August 13, 2021	September 10, 2021	June 29, 2021
$0.85	$0.85	May 13, 2021	May 14, 2021	June 10, 2021	May 03, 2021
$0.85	$0.85	February 11, 2021	February 12, 2021	March 10, 2021	December 14, 2020
$0.74	$0.74	November 12, 2020	November 13, 2020	December 10, 2020	October 19, 2020
$0.74	$0.74	August 13, 2020	August 14, 2020	September 10, 2020	July 15, 2020
$0.74	$0.74	May 14, 2020	May 15, 2020	June 10, 2020	May 04, 2020

See full dividend history

Peers: Drug Manufacturers - General

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company	Market Cap	Price	EPS	P/E Ratio	P/B Ratio
Johnson & Johnson JNJ	$371.68B	$154.38	$13.88	$11.30	$5.77
Bristol-Myers Squibb Company BMY	$115.40B	$56.90	$3.88	$13.23	$3.61
AbbVie Inc. ABBV	$341.24B	$193.11	$2.75	$56.34	$26.45
Pfizer Inc. PFE	$146.27B	$25.81	$0.38	$76.67	$1.83
Merck & Co., Inc. MRK	$223.09B	$88.19	$0.14	$778.71	$7.56
Amgen Inc. AMGN	$158.79B	$295.40	$7.62	$34.22	$0.00
Gilead Sciences, Inc. GILD	$121.79B	$97.72	$4.54	$17.85	$4.43